142 related articles for article (PubMed ID: 15809548)
21. Effect of tiotropium on neural respiratory drive during exercise in severe COPD.
Qin YY; Li RF; Wu GF; Zhu Z; Liu J; Zhou CZ; Guan WJ; Luo JY; Yu XX; Ou YM; Jiang M; Zhong NS; Luo YM
Pulm Pharmacol Ther; 2015 Feb; 30():51-6. PubMed ID: 25449059
[TBL] [Abstract][Full Text] [Related]
22. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD.
Peters MM; Webb KA; O'Donnell DE
Thorax; 2006 Jul; 61(7):559-67. PubMed ID: 16467067
[TBL] [Abstract][Full Text] [Related]
23. Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD.
Guenette JA; Raghavan N; Harris-McAllister V; Preston ME; Webb KA; O'Donnell DE
Respir Med; 2011 Dec; 105(12):1836-45. PubMed ID: 21917440
[TBL] [Abstract][Full Text] [Related]
24. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD.
Mahler DA; Murray JA; Waterman LA; Ward J; Kraemer WJ; Zhang X; Baird JC
Eur Respir J; 2009 Apr; 33(4):771-7. PubMed ID: 19213787
[TBL] [Abstract][Full Text] [Related]
25. Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease.
Deschênes D; Pepin V; Saey D; LeBlanc P; Maltais F
J Cardiopulm Rehabil Prev; 2008; 28(3):208-14. PubMed ID: 18496322
[TBL] [Abstract][Full Text] [Related]
26. Physiological effects of roflumilast at rest and during exercise in COPD.
O'Donnell DE; Bredenbröker D; Brose M; Webb KA
Eur Respir J; 2012 May; 39(5):1104-12. PubMed ID: 21965226
[TBL] [Abstract][Full Text] [Related]
27. Salmeterol reduces dyspnea and improves lung function in patients with COPD.
Ramirez-Venegas A; Ward J; Lentine T; Mahler DA
Chest; 1997 Aug; 112(2):336-40. PubMed ID: 9266866
[TBL] [Abstract][Full Text] [Related]
28. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest.
Boni E; Corda L; Franchini D; Chiroli P; Damiani GP; Pini L; Grassi V; Tantucci C
Thorax; 2002 Jun; 57(6):528-32. PubMed ID: 12037229
[TBL] [Abstract][Full Text] [Related]
29. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.
O'Donnell DE; Lam M; Webb KA
Am J Respir Crit Care Med; 1999 Aug; 160(2):542-9. PubMed ID: 10430726
[TBL] [Abstract][Full Text] [Related]
30. Comparison of dyspnea ratings during submaximal constant work exercise with incremental testing.
Franco MJ; Olmstead EM; Tosteson AN; Lentine T; Ward J; Mahler DA
Med Sci Sports Exerc; 1998 Apr; 30(4):479-82. PubMed ID: 9565926
[TBL] [Abstract][Full Text] [Related]
31. Residual reversibility in COPD patients already on long-acting bronchodilator: The OscilloRevers Study.
Le Rouzic O; Picaud M; Salvator H; Bautin N; Devillier P; Perez T
Respir Med Res; 2024 Jun; 85():101082. PubMed ID: 38280281
[TBL] [Abstract][Full Text] [Related]
32. Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease.
Ikeda A; Nishimura K; Koyama H; Tsukino M; Mishima M; Izumi T
Thorax; 1996 Jan; 51(1):48-53. PubMed ID: 8658369
[TBL] [Abstract][Full Text] [Related]
33. Sensory-mechanical effects of a dual bronchodilator and its anticholinergic component in COPD.
O'Donnell DE; Elbehairy AF; Faisal A; Neder JA; Webb KA;
Respir Physiol Neurobiol; 2018 Jan; 247():116-125. PubMed ID: 28993264
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD.
Ayers ML; Mejia R; Ward J; Lentine T; Mahler DA
Eur Respir J; 2001 Jun; 17(6):1132-7. PubMed ID: 11491155
[TBL] [Abstract][Full Text] [Related]
35. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.
Levin DC; Little KS; Laughlin KR; Galbraith JM; Gustman PM; Murphy D; Kram JA; Hardie G; Reuter C; Ostransky D; McFarland K; Petty TL; Silvers W; Rennard SI; Mueller M; Repsher LH; Zuwallack RL; Vale R
Am J Med; 1996 Jan; 100(1A):40S-48S. PubMed ID: 8610716
[TBL] [Abstract][Full Text] [Related]
36. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
37. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.
O'Donnell DE; Sciurba F; Celli B; Mahler DA; Webb KA; Kalberg CJ; Knobil K
Chest; 2006 Sep; 130(3):647-56. PubMed ID: 16963658
[TBL] [Abstract][Full Text] [Related]
38. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
39. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Voduc N; Fitzpatrick M; Webb KA
Eur Respir J; 2004 Jul; 24(1):86-94. PubMed ID: 15293609
[TBL] [Abstract][Full Text] [Related]
40. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD.
Wolkove N; Kamel H; Rotaple M; Baltzan MA
Chest; 2002 Mar; 121(3):702-7. PubMed ID: 11888949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
